8-K: INmune Bio Presents Promising Data on INB03 for High-Risk Breast Cancer at AACR 2024

INmune Bio is presenting data at AACR 2024 showing that INB03, a soluble TNF inhibitor, demonstrates potential in treating high-risk breast cancer by modulating immune checkpoints and reducing metastasis.

Summary

• INmune Bio presented data on INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor, at the American Association of Cancer Research (AACR) annual meeting.
• INB03 targets soluble TNF (sTNF) and has shown promise in treating high-risk MUC4 expressing HER2+ and triple-negative breast cancer (TNBC).
• Studies indicate that INB03 decreases immune checkpoint proteins on T cells and macrophages, and reduces the metastatic potential of TNBC.
• In a HER2+ breast cancer model, combining INB03 with an anti-HER2 antibody resulted in decreased tumor growth, increased T cell infiltration, and a shift in macrophage polarization from immunosuppressive to anti-tumor.
• The combination also doubled antibody-dependent cellular phagocytosis (ADCP) and decreased the expression of immune checkpoint proteins.
• In TNBC, MUC4 expression was found to be a biomarker for poor survival and increased metastasis risk, with INB03 decreasing MUC4 expression and reducing invasive capacity.
• In a preclinical model of TNBC, the combination of INB03 and anti-PD1 checkpoint antibodies significantly reduced lung metastasis.
• INB03 is proposed as a pan-immune checkpoint modulator, downregulating multiple immune checkpoint proteins on both T cells and macrophages.
• The company is seeking a partner to advance the clinical development of INB03 in combination therapy.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical data for INB03, highlighting its potential as a novel cancer therapy. The company is actively seeking partnerships, which is a positive sign for future development. However, the early stage of clinical trials and the need for funding temper the overall sentiment.

Positives

• INB03 demonstrates a novel approach to cancer treatment by targeting soluble TNF.
• The combination of INB03 with other therapies shows synergistic effects in reducing tumor growth and metastasis.
• INB03 has shown to be safe and well tolerated in a Phase I trial.
• The research identifies MUC4 as a potential biomarker for predicting treatment resistance and guiding therapy decisions.
• The company is actively seeking partnerships to advance clinical development.

Negatives

• The research is still in preclinical stages, and clinical trials are needed to confirm the findings in humans.
• The company is seeking a partner to advance clinical development, suggesting they may not have the resources to do so alone.
• The document mentions that clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.

Risks

• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the company to continue its operations is a risk.
• There is a risk that INB03, XPro1595, and INKmune may not be approved by the FDA or any regulatory body.
• The company's business, research, product development, regulatory approval, marketing and distribution plans and strategies are subject to risks and uncertainties.

Future Outlook

The company plans to expand its business development efforts to find a partner to advance the clinical development of INB03 in combination therapy. They also plan to expand their patent portfolio covering INB03 for oncology indications.

Management Comments

• Dr. Schillaci proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.
• Dr. Schillaci stated that soluble TNF shields tumors from immune attacks, and INB03 can counteract these effects.
• RJ Tesi M.D., CEO of INmune Bio, stated that MUC4 expression in high-risk breast cancer subtypes is a predictor of resistance to therapy.
• Joshua Schoonover, General Counsel of INmune Bio, stated that the findings support the expansion of their patent portfolio.

Industry Context

This announcement is relevant to the broader trend of developing novel immunotherapies for cancer, particularly those that target the tumor microenvironment and overcome resistance to existing treatments. The focus on soluble TNF and immune checkpoint modulation aligns with current research in the field.

Comparison to Industry Standards

• The approach of targeting soluble TNF is a novel strategy compared to traditional immune checkpoint inhibitors that target specific proteins like PD-1 or CTLA-4.
• The results showing a 3-fold increase in T cell infiltration and a doubling of ADCP are significant compared to some other immunotherapies.
• The identification of MUC4 as a biomarker for poor survival in TNBC is consistent with the growing focus on personalized medicine in oncology.
• The preclinical results showing a dramatic decrease in lung metastasis with the combination therapy are promising and warrant further investigation in clinical trials.

Stakeholder Impact

• Shareholders may view the positive preclinical data as a positive development.
• Patients with high-risk breast cancer may benefit from the development of INB03.
• The company's employees may be impacted by the potential for growth and expansion.
• Potential partners may be interested in collaborating with the company on the development of INB03.

Next Steps

• The company plans to expand its business development efforts to find a partner for clinical development.
• The company plans to expand its patent portfolio covering INB03 for oncology indications.
• The company will continue to explore cancer treatment indications and commercial applications of INB03.

Key Dates

Keywords

INB03, Breast Cancer, Immunotherapy, Soluble TNF, MUC4, Immune Checkpoint, Metastasis, HER2+, TNBC, Macrophages, T cells, AACR